Viscera Labs

Viscera Labs is a private, preclinical-stage biotech targeting bile acid-mediated disorders, a category encompassing liver diseases like primary sclerosing cholangitis (PSC) and metabolic conditions such as non-alcoholic steatohepatitis (NASH). The company has assembled a compact, experienced leadership team and a distinguished board of scientific consultants from top U.S. academic institutions. Operating in a high-need therapeutic area with growing market potential, Viscera Labs is positioned to develop novel therapeutics, though it faces the typical risks of early-stage drug development and significant competition.

Focus on developing novel pharmacological agents targeting bile acid synthesis, signaling, or transport pathways for therapeutic intervention.

The space for bile acid disorder therapeutics is highly competitive, especially in NASH, with numerous biopharma companies pursuing FXR agonists, ASK1 inhibitors, and other mechanisms. In cholestatic diseases, Intercept Pharmaceuticals' Ocaliva is an established FXR agonist, and other companies are advancing next-generation candidates. Viscera Labs will need to demonstrate clear differentiation in efficacy, safety, or dosing to capture market share.